CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D009767: Obesity, Morbid NIH

(Synonyms: Obesity, Morb, Obesity, Morbid)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug375 Bariatric procedures Wiki 0.71
drug2858 Telephonic interview during the Italian lockdown. Wiki 0.71

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D009765 Obesity NIH 0.25
D011024 Pneumonia, Viral NIH 0.09
D014777 Virus Diseases NIH 0.08
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001513 Obesity HPO 0.25
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials


1 Was it Right to Stop Bariatric Surgery During COVID-19 Lockdown?

From the beginning of March 2020, lockdown regimens prevented patients with obesity from receiving bariatric surgery. Surgical emergencies and oncological procedures were the only operations allowed in public hospitals. Consequently, patients with morbid obesity were put in a stand-by situation. With the aim at exploring physical and psychological conditions of the investigators future bariatric surgery patients, the investigators built a Questionnaire concerning obesity and COVID-19.

NCT04453579 Obese Morbid Obesity Behavioral: Telephonic interview during the Italian lockdown.
MeSH:Obesity, Morbid

Primary Outcomes

Description: exploring physical and psychological conditions of our future bariatric surgery patients

Measure: Psychological conditions

Time: 2 months

2 Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.

The first person-to-person Coronavirus disease (COVID-19) transmission in Italy was reported on Feb 21st, 2020, causing one of the most massive outbreak in Europe so far that stopped immediately all elective surgical procedures. Bariatric surgery represents the most effective treatment to obtain an important, long-term weight loss and comorbidities' resolution, including respiratory disorders. A sensitive decrease of epidemic has been observed lately and a gradual and progressive stop of the lockdown (phase 2-3) was planned, when the virus is supposed to be under control and protocols are guiding the restart of the elective bariatric surgery. Several questions are currently open: Laparoscopic bariatric surgery is safe in the phase 2-3? What's the expected complications rate? The actual hospital protocols are effective to minimize the risk of postoperative COVID-19 infection? Aim: to analyse results of bariatric surgery during phase 2-3 COVID-19 pandemic in Italy. Primary end point: 30 days COVID-19 infection, mortality and complications. Secondary end points: readmission rate 30 days, reoperations for any reason related to surgery. Study design: prospective multicenter observational. Setting: Italian National Health Service 8 high-volume bariatric centres. Enrollment criteria: No previous Covid-19 infection; Primary, standard IFSO approved bariatric procedures; No concomitant procedure; No previous major abdominal surgery; >18<60 years old; Compensated comorbidities; Official SICOB's surgical informed consent given, including COVID-19 addendum; Adherence to very restrictive protocols regarding: hospital admission, management of in-hospital patients and after discharge. Follow-up: scheduled outpatient visit 30th postoperative day. Data evaluation: all the cases performed during July/December 2020 will be collected in a prospective database. Patients operated during the period July/December 2019 in the same centers will be considered comparative group (control). Expected results: Transparent information to the patients, and the introduction of the COVID-19 protocol concerning patients and health-professionals protection, should guarantee a safe restart of bariatric surgery in Italy. The network of 8 high-volume centers sharing information and protocols in this "unexplored" period will be a guarantee for patients' safety. Bariatric surgery should induce a postoperative amelioration of the comorbidities reducing the risks in case of a second outbreak.

NCT04480034 Bariatric Surgery Candidate Covid19 Complication of Surgic Complication of Surgical Procedure Pneumonia, Viral Viral Infection Obesity, Morbid Safety Issues Readmission Procedure: Bariatric procedures
MeSH:Pneumonia, Viral Pneumonia Obesity Obesity, Morbid Virus Diseases
HPO:Obesity Pneumonia

Primary Outcomes

Description: Postbariatric surgery COVID-19 infection, mortality and complications

Measure: Postoperative COVID-19 infection

Time: 30 postoperative days

Secondary Outcomes

Description: Complications, reoperations for any reason related to bariatric surgery.

Measure: Complications related to bariatric surgery

Time: 30 postoperative days


HPO Nodes